VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

S. pneumoniae CbpA Protein Vaccine
Vaccine Information
  • Vaccine Name: S. pneumoniae CbpA Protein Vaccine
  • Target Pathogen: Streptococcus pneumoniae
  • Target Disease: Pneumonia
  • Vaccine Ontology ID: VO_0004005
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: N-terminal fragment of choline binding protein A (CbpA) (Ogunniyi et al., 2001).
  • CbpA gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • Adjuvant: MPL vaccine adjuvant
    • Adjuvant name: MPL vaccine adjuvant
    • VO adjuvant ID: VO_0001250
    • Description: Monophospholipid A (MPL) and aluminium phosphate (AlPO4) (Ogunniyi et al., 2001).
  • Adjuvant: aluminum phosphate vaccine adjuvant
  • Immunization Route: Intraperitoneal injection (i.p.)
Host Response

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: 5- to 6-week-old male BALB/c mice (13 to 15 per group) were immunized intraperitoneally with either adjuvant alone, adjuvant plus CbpA, or CbpA alone. Each mouse received three doses of 10 μg of each protein antigen in either formulation (AlPO4 or MPL plus AlPO4) at 12- to 14-day intervals (Ogunniyi et al., 2001).
  • Challenge Protocol: Intraperitoneal-challenge experiments were carried out 2 weeks after the third immunization using a highly virulent capsular type 2 strain (D39). Groups of immunized BALB/c mice were infected with either 1.3 × 105 or 1.3 × 107 CFU of the challenge strain. The challenge dose was equivalent to approximately 103 or 105 times the 50% lethal dose (LD50), respectively, for BALB/c mice. The mice were closely monitored for 21 days, and the survival time of each mouse was recorded (Ogunniyi et al., 2001).
  • Efficacy: CbpA was able to protect mice from intraperitoneal challenge with medium to very high doses of a highly virulent capsular type 2 pneumococcal strain, D39 (Ogunniyi et al., 2001).
References
Ogunniyi et al., 2001: Ogunniyi AD, Woodrow MC, Poolman JT, Paton JC. Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA. Infection and immunity. 2001; 69(10); 5997-6003. [PubMed: 11553536].